KERYX BIOPHARMACEUTICALS INC's ticker is KERX and the CUSIP is 492515101. A total of 154 filers reported holding KERYX BIOPHARMACEUTICALS INC in Q2 2015. The put-call ratio across all filers is 0.73 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $110,000 | -9.1% | 32,231 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $121,000 | -8.3% | 32,231 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $132,000 | -12.0% | 32,231 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $150,000 | -34.5% | 32,231 | 0.0% | 0.00% | -50.0% |
| Q3 2017 | $229,000 | -1.7% | 32,231 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $233,000 | +17.1% | 32,231 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $199,000 | +5.3% | 32,231 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $189,000 | +10.5% | 32,231 | 0.0% | 0.00% | +100.0% |
| Q3 2016 | $171,000 | -19.7% | 32,231 | 0.0% | 0.00% | -50.0% |
| Q2 2016 | $213,000 | +41.1% | 32,231 | 0.0% | 0.00% | +100.0% |
| Q1 2016 | $151,000 | +98.7% | 32,231 | +114.0% | 0.00% | 0.0% |
| Q4 2015 | $76,000 | +43.4% | 15,064 | 0.0% | 0.00% | – |
| Q3 2015 | $53,000 | -64.7% | 15,064 | 0.0% | 0.00% | -100.0% |
| Q2 2015 | $150,000 | – | 15,064 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management I, LLC | 1,312,006 | $16,990,000 | 16.50% |
| VHCP Management, LLC | 1,000,273 | $12,954,000 | 6.97% |
| Cormorant Asset Management, LP | 1,700,000 | $22,015,000 | 6.39% |
| HARVEY CAPITAL MANAGEMENT INC | 890,500 | $11,531,000 | 4.76% |
| INSIGHT CAPITAL RESEARCH & MANAGEMENT INC | 859,672 | $11,133,000 | 2.50% |
| Rhenman & Partners Asset Management AB | 400,000 | $5,180,000 | 2.03% |
| SECTORAL ASSET MANAGEMENT INC | 2,758,950 | $35,728,000 | 1.54% |
| NORTHPOINTE CAPITAL LLC | 1,289,711 | $16,701,000 | 1.47% |
| Knoll Capital Management, LLC | 200,000 | $2,592,000 | 1.30% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,483,260 | $19,208,000 | 1.00% |